Title:
PROTEIN RECEPTOR TYROSINE KINASE INHIBITOR COMPOSITION
Document Type and Number:
Japanese Patent JP2018002741
Kind Code:
A
Abstract:
PROBLEM TO BE SOLVED: To provide a protein receptor tyrosine kinase inhibitor.SOLUTION: The present invention relates to a novel synthesis substituted heterocyclic compound and pharmaceutical composition containing the same that can inhibit or antagonize a receptor tyrosine kinase family, Tropomyosin (Tropomysosin) related kinase (Trk), particularly nerve growth factor (NGF) receptor, TrkA. And further, the present invention also relates to a use of said compound in the treatment and/or prophylaxis of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or damage associated with dysmyelination or demyelination, or a disease or disorder associated with NGF receptor TrkA abnormal activity.SELECTED DRAWING: None
Inventors:
JAY JIE-QIANG WU
WANG LING
WANG LING
Application Number:
JP2017197589A
Publication Date:
January 11, 2018
Filing Date:
October 11, 2017
Export Citation:
Assignee:
MUNDIPHARMA INT CORP LTD
International Classes:
C07D261/20; A61K31/4545; A61K31/4709; A61K31/4738; A61K31/495; A61K31/496; A61K31/498; A61K31/538; A61K31/5383; A61K31/5415; A61K31/55; A61K31/551; A61K31/554; A61P7/02; A61P9/10; A61P17/06; A61P25/00; A61P29/00; A61P35/00; A61P43/00; C07D215/227; C07D221/12; C07D223/18; C07D241/44; C07D265/36; C07D279/16; C07D281/10; C07D295/13; C07D407/12; C07D413/12; C07D417/12; C07D471/04; C07D471/14; C07D493/04; C07D495/04; C07D498/04; C07D513/04
Attorney, Agent or Firm:
Hidesaku Yamamoto
Natsuki Morishita
Takatoshi Iida
Daisuke Ishikawa
Kensaku Yamamoto
Natsuki Morishita
Takatoshi Iida
Daisuke Ishikawa
Kensaku Yamamoto
Previous Patent: Medical treatment of a digestive system disease
Next Patent: The salt form of human histone methyl transferase EZH2 inhibitor
Next Patent: The salt form of human histone methyl transferase EZH2 inhibitor